



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/107, 9/48, 38/13</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/40051</b> <b>(43) International Publication Date:</b> 17 September 1998 (17.09.98)
<b>(21) International Application Number:</b> PCT/US98/04899 <b>(22) International Filing Date:</b> 12 March 1998 (12.03.98)  <b>(30) Priority Data:</b> 08/820,392 12 March 1997 (12.03.97) US  <b>(71) Applicant:</b> ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).  <b>(72) Inventors:</b> AL-RAZZAK, Laman, A.; 1111 South Waukegan Road #7, Lake Forest, IL 60045 (US). CONSTANTINIDES, Panayiotis, Pericleous; 95 Berkshire Court, Gurnee, IL 60031 (US). GAO, Rong; 4255 Greenleaf Court #201, Park City, IL 60085 (US). KAUL, Dilip; 4334 Buckingham Drive, Gurnee, IL 60064 (US). LIPARI, John, M.; 6600 Apollo Drive, Racine, WI 53406 (US). MAZER, Terrence, B.; 6897 Roundelay Road North, Reynoldsburg, OH 43068 (US). MCCHESENEY-HARRIS, Lisa, L.; 105 Lancaster Place, Vernon Hills, IL 60061 (US).  <b>(74) Agents:</b> DANCKERS, Andreas, M. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).		<b>(81) Designated States:</b> CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> LIPOPHILIC BINARY SYSTEMS FOR THE ADMINISTRATION OF LIPOPHILIC COMPOUNDS  <b>(57) Abstract</b>  Binary pharmaceutical formulations comprising (i) a cyclosporine compound, (ii) a lipophilic phase and (iii) a surfactant provide bioavailability of the active ingredient which is equivalent to that provided by ternary compositions, but without the need for a hydrophilic phase.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

LIPOPHILIC BINARY SYSTEMS FOR THE ADMINISTRATION OF  
LIPOPHILIC COMPOUNDS

Technical Field

- 5       The present invention relates to pharmaceutical compositions containing lipophilic medicinal compounds, suitable for oral as well as topical, local and other routes of administration. In particular, the invention relates to binary formulations of cyclosporines which comprise a lipophilic phase and one or more surfactants, but which lack a hydrophilic phase.

10   Background of the Invention

- Pharmaceutical compounds which are highly lipophilic present considerable formulation challenges. Because of their low solubility in aqueous media, including the contents of the mammalian digestive tract, they often suffer from poor or variable bioavailability when given orally or via other routes that require transmembrane absorption.
- 15   Examples of such medicinal compounds include the immunosuppressants cyclosporine and FK506 (tacrolimus); protease inhibitors such as ritonavir; central nervous system drugs such as tiagabine; and anti-inflammatory agents such as zileuton and other 5-lipoxygenase inhibitors.

- One method of formulating lipophilic compounds is to combine them with glyceride carriers which form emulsions upon mixing with water. Emulsions are described, for
- 20   example, in U.S. Patent No. 4,388,307 issued to Cavanak, a commercial example of which is the cyclosporine-containing product SANDIMMUNE® oral solution. This product comprises the emulsifier LABRAFIL® (a polyoxyethylated kernel oil), olive oil and alcohol, with the compound cyclosporin A present at a concentration of 100 mg/ml. Cavanak suggests that such glyceride carriers may assist in alleviating problems of physical instability such as precipitation
- 25   of the drug from solution, and may also enable higher plasma concentrations.

- More recently, it has been proposed that a preferred vehicle for lipophilic compounds is the so-called "self-emulsifying drug delivery system" which, when exposed to an aqueous medium, forms a fine oil-in-water emulsion with little or no agitation. The property of self-emulsification permits such formulations to be administered in concentrated form, as for
- 30   example in a hard gelatin or soft elastic capsule, with the expectation that a fine emulsion will be formed in the digestive tract. Moreover, it has been suggested that self-emulsifying formulations, when given orally, may offer improvements in both the rate and extent of absorption of the medicinal compound and can result in reduced variability in plasma concentration profiles. (See, S. A. Charman *et al.*, Pharmaceutical Research 9(1):87-93
- 35   (1992), and N. H. Shah *et al.*, International Journal of Pharmaceutics 106:15-23 (1994).) Additionally, emulsions which have been prepared by combining a self-emulsifying

pre-concentrate with an aqueous medium appear to benefit, due to their small droplet diameter, from improved physical stability when compared with conventional emulsions.

Previously-disclosed self-emulsifying systems include those in which a lipophilic drug is combined with mixtures of (i) medium-chain triglycerides and nonionic surfactants,  
5 (ii) vegetable oils and partial glycerides such as polyglycolized glycerides or medium-chain mono- and diglycerides, or (iii) vegetable oils and nonionic surfactants such as polysorbate 80 or PEG-25 glyceryl trioleate. Other formulations have been characterized as self-emulsifying, including the above-mentioned SANDIMMUNE® cyclosporine formulation; however, these additionally contain a substantial amount of a solubilizing agent or solvent such as ethanol,  
10 rendering them unsuitable for certain uses such as filling into gelatin capsules, from which the solvent can readily escape.

Self-emulsifying formulations which seek to overcome this drawback are disclosed by Hauer *et al.* in U.S. Patent No. 5,342,625. In these formulations, a "microemulsion pre-concentrate" of a cyclosporine is formed by combining the drug with (I) a hydrophilic phase,  
15 (II) a lipophilic phase, and (III) a surfactant, as well as optional thickeners, anti-oxidants or other excipients. Unfortunately, the complexity of these ternary formulations may make them costly and difficult to manufacture.

There exists, consequently, a need for formulations of lipophilic drugs such as cyclosporines that are simpler and easier to prepare than the ternary systems described above.  
20 Kurihara *et al.*, in U.S. Patent No. 4,990,337, propose cyclosporine-containing formulations that comprise medium-chain, C<sub>6</sub>-to-C<sub>10</sub>, mono- and diglycerides. However, additional formulations are sought which offer an advantageous combination of physical stability, desirable pharmacokinetics and/or ease of manufacture.

## 25 Summary of the Invention

Surprisingly, it has now been found that many of the problems associated with the administration of lipophilic compounds such as cyclosporines may be overcome by the use of a simple binary system of excipients comprising only a lipophilic phase and a surfactant (or mixture of surfactants). In particular, the invention provides pharmaceutical compositions  
30 containing a cyclosporine compound in combination with a lipophilic phase and a surfactant, but not containing hydrophilic solvents. Such binary formulations are novel; moreover, the cyclosporine-containing formulations of the present invention are stable, simple to prepare, and commercially attractive by virtue of their pharmacokinetic properties.

As used herein, the terms "binary system", "binary composition" and "binary system of  
35 excipients" include those formulations and compositions which contain, in addition to the active ingredient or ingredients, a combination of at least one lipophilic solvent and at least one

surfactant in the absence of any hydrophilic solvents or excipients (such as water). For example, freeze-dried formulations that contain even a minimal amount of water are not considered to be binary compositions as that term is used herein.

To prepare the pharmaceutical compositions of the invention, a binary system of the invention is combined with a lipophilic active ingredient, such as a cyclosporine compound. The term "cyclosporine" as used herein refers to one or more of the cyclosporines, and especially to cyclosporin A, as described in United States Patent No. 4,117,118 issued to Härril *et al.* and incorporated herein by reference.

If desired, binary compositions of the present invention may be selected which are bioequivalent to compositions that use the ternary excipient systems of the prior art; that is, when such binary and ternary compositions containing equal amounts of active ingredient are administered separately to comparable test subjects, about the same amount of active ingredient will be delivered to the subjects' bloodstreams by the inventive composition as by the ternary composition. The amount of drug delivered (or other pharmacokinetic property) may be measured by any of the methods known in the art, as for example the maximum plasma concentration ( $C_{max}$ ), the time from dosing until the maximum plasma concentration is reached ( $T_{max}$ ), and the integral or time-course of plasma concentration over time (area under the curve, or AUC).

As described earlier, the binary systems of the invention comprise a lipophilic phase and one or more surfactants. Unless otherwise specified, the term "lipophilic component" or "lipophilic solvent" refers to a pharmaceutically acceptable solvent, carrier, excipient, or diluent that has an affinity for fats or lipids. The term "lipophilic phase" refers to the portion of the composition that is lipophilic, which phase can be a single component or a mixture of components.

The term "surfactant" as used herein describes that portion of a composition of the invention which comprises one or more surfactants. The surfactants may be any of the known pharmaceutically acceptable surfactants, including nonionic, anionic and cationic surfactants. A single surfactant or a mixture of surfactants may be used.

Unless otherwise specified, all percentages are weight percentages based on the total weight of the pharmaceutical composition.

Detailed Description of the Invention

In binary compositions according to the present invention, the lipophilic phase may comprise one or more of any of the known pharmaceutically acceptable lipophilic solvents or excipients that are capable of dissolving a cyclosporine compound. Suitable classes of lipophilic solvents include, for example, fatty acid esters of glycerol; fatty acid esters of propylene glycol; vegetable oils; mineral oils; and acetylated mono- and diglycerides. Preferred solvents include fatty acid esters of propylene glycol as well as C<sub>12</sub> and longer fatty acid esters of glycerol.

Particular lipophilic phase components useful in the compositions of the invention include, but are not limited to, propylene glycol mono- and/or dicaprylate/caprates; propylene glycol mono- and/or dilaurate (for example, LAUROGLYCOL<sup>®</sup>, available from Gattefossé Corporation, Westwood, New Jersey); vegetable oil; corn oil; sesame oil; safflower oil; peanut oil; olive oil; cottonseed oil; glyceryl monostearate; glyceryl caprylate/caprate (for example, CAPMUL<sup>®</sup> MCM, available from Abitec Corporation, Columbus, Ohio); glyceryl mono-, di- and/or trioleate (for example, CAPMUL<sup>®</sup> GMO, available from Abitec Corporation), or PECEOL<sup>®</sup>, available from Gattefossé); caprylic/capric triglyceride (for example, NEOBEE<sup>®</sup> M-5, available from Stepan Corporation); and fractionated coconut oils, such as the MIGLYOL<sup>®</sup> 810, 812 and 818 products, available from Huls, Ltd. (Wolverton Mill S., UK). Of these, glyceryl caprylate/caprate, for example, CAPMUL<sup>®</sup> MCM is preferred.

The lipophilic phase, comprising one or more lipophilic solvents, generally comprises about 10 to 90% by weight of the pharmaceutical composition. The precise proportion will vary depending on the nature of the lipophilic solvent(s) used, the amount of active ingredient present, the dosage type, and other factors known to those of skill in the art. Preferably the lipophilic phase comprises about 20 to 85% by weight, and more preferably about 40 to 60% by weight of the pharmaceutical composition of the invention.

The binary systems of the present invention also comprise at least one surfactant in combination with the above lipophilic phase. While not intending to be bound by theory, the surfactant is believed to assist in the formation of a micellar system or a microsuspension upon contact with an aqueous medium such as gastrointestinal fluids in a way that the solubility of the active ingredient is enhanced. The size of the particles present in this micellar or microsuspension system are in the sub-micron (sub-micrometer) range and can vary over time. Any of the known pharmaceutically acceptable surfactants may be used, including nonionic, anionic, cationic, and combinations thereof. Of these, nonionic surfactants are preferred; especially preferred are (i) surfactants having a hydrophile/lipophile balance (HLB) of 10 or more or (ii) mixtures of surfactants which, when combined, exhibit a final HLB of 10 or more.

Examples of suitable surfactants include, but are not limited to, polyoxyethylene derivatives of natural or hydrogenated vegetable oils such as castor oil; polyoxyethylene-sorbitan esters of fatty acids, such as mono-, di- and tri-lauryl, palmityl, stearyl and oleyl; polyoxyethylene fatty acid esters; polyoxyethylene-polyoxypropylene copolymers; alkyl/dialkylsulfate, sulfonate or sulfosuccinate salt; sodium lauryl sulfate; phospholipids such as lecithins; trans-esterification products of natural vegetable oil triglycerides and polyalkylene polyols; sorbitan fatty acid esters; pentaerythritol fatty acid esters and polyalkylene glycol ethers; and the like. The surfactants may be used alone or in combination.

Although any pharmaceutically acceptable surfactant may be used in the binary system of the invention, certain surfactants are preferred. These include polyoxyethylene castor oil derivatives, such as polyoxyethylene-glycerol-triricinoleate, also known as polyoxyl 35 castor oil (CREMOPHOR<sup>®</sup> EL), or polyoxyl 40 hydrogenated castor oil (CREMOPHOR<sup>®</sup> RH40, both available from BASF Corp.); mono-fatty acid esters of polyoxyethylene (20) sorbitan, such as polyoxyethylene(20)sorbitan monooleate (TWEEN<sup>®</sup> 80, available), polyoxyethylene monostearate (TWEEN<sup>®</sup> 60), polyoxyethylene (20) sorbitan monopalmitate (TWEEN<sup>®</sup> 40), polyoxyethylene (20) sorbitan monolaurate (TWEEN<sup>®</sup> 20, all available from ICI Surfactants, Wilmington, Delaware); polyglyceryl esters, such as polyglyceryl oleate; and LABRAFIL<sup>®</sup> M1944 CS polyoxyethylated kernel oil (available from Gattefossé Corporation).

Of the above, the polyoxyethylene castor oil derivatives are particularly preferred, with CREMOPHOR<sup>®</sup> EL and CREMOPHOR<sup>®</sup> RH40 the most preferred. As the proportion of this type of surfactant in the compositions of the invention increases above about 10% by weight, and upon dilution of the formulation with water or juice, the particle size of the resulting microemulsion or micellar solution decreases. For example, at a surfactant concentration of about 10% by weight, the particle size of the diluted formulation is generally less than about 120 nm; at a concentration of about 30% by weight the particle size is generally less than about 100 nm; and at a concentration of about 50% by weight the particle size is generally less than about 50 nm.

The surfactant component generally comprises about 5 to 90% by weight of the composition. Preferably the surfactant comprises about 10 to 60% by weight of the composition, and more preferably about 30 to 50% by weight.

The active ingredient, for example, a cyclosporine, will normally be present in amounts ranging from about 0.01 to 50% by weight of the composition. In a preferred embodiment of the invention the active ingredient is present in an amount ranging between about 5 and 15% by weight, with about 10% by weight particularly preferred. Of course, those of skill in the art understand that the amount of active ingredient present in the composition will vary with the particular situation, including the mode of administration, the size and condition of the subject, and other factors.

If desired, the compositions of the invention may additionally comprise other pharmaceutically acceptable excipients such as fillers, diluents, flavoring agents, coloring agents, antioxidants, preservatives such as antibacterial or antifungal agents, and the like. Such additives, if present, may comprise about 0.01 to 10% by weight of the composition.

5 The pharmaceutical compositions of the invention may be administered by any of the methods known in the art. Such methods include but are not limited to oral administration of a suspension formed by mixing the composition of the invention with an aqueous medium such as water, milk or juice; in the form of a soft elastic or hard gelatin capsule into which the composition of the invention has been directly placed; parenteral administration including  
10 intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection or infusion; or topical administration, such as by ointments, drops or transdermal patches. Topical formulations, intended for administration to the skin or mucosa including the surfaces of the lung and eye, may be prepared directly from the compositions of the invention or from a suspension or microsuspension prepared by combining an appropriate composition  
15 of the invention with an aqueous diluent. Such topical formulations may include additional excipients as necessary, for example to modify consistency or the rate of absorption of the active ingredient.

In preparing the compositions of the present invention, the above components may be combined in any order with mixing or light agitation to ensure complete solubilization. If  
20 necessary, the mixture may be warmed slightly to aid liquification and dissolution. If all components of the formulation are liquid at ambient temperatures (about 25 to 30°C), they may be combined without heating.

The pharmaceutical compositions and formulations of the invention may be administered in a sufficient amount, and for a sufficient time, as required to provide the desired  
25 therapeutic effect. The specific therapeutically effective dosage level will be dependent on a number of factors including the specific condition being treated, the severity of the disorder, the activity of the particular active ingredient, the specific formulation employed, the time and method of administration, the duration of treatment, and other factors which are well known in the medical arts.

30 The invention will be better understood by reference to the following examples, which are understood to be illustrative only and are not intended as a limitation upon the scope of the invention.

Each of the compositions was prepared by placing the component or components of the  
35 lipophilic phase into a suitable vessel, heating to a temperature of about 40 to 45°C, and mixing until uniform. The surfactant or surfactants were pre-melted, if necessary, and added, with continuous mixing, while maintaining the temperature at about 40 to 45°C. The active



ingredient(s) were then added, stirring continuously, with the temperature maintained at about 40 to 45°C. The product was transferred to appropriate containers and allowed to cool.

The following table shows the chemical identity of the various products used in the example formulations:

5

Table 1

<u>Trade Name</u>	<u>Chemical Designation</u>
TWEEN® 80	Polyoxyethylene (20) sorbitan monooleate
MIGLYOL® 812	Caprylic/capric triglyceride
CREMOPHOR® EL	Polyoxyl 35 castor oil
CREMOPHOR® RH40	Polyoxyl 40 hydrogenated castor oil
CAPMUL® MCM	Mono- and diglyceryl caprylate/caprate
GELUCIRE® 33/01	C <sub>8</sub> /C <sub>18</sub> triglycerides from hydrogenated palm oil
MAISINE®	Transesterified mono-, di- and triglycerides from corn oil
CAPMUL® GMO	Glyceryl oleate (mono-, di- and triesters)
POLOXAMER® 237	Polyoxypropylene/polyoxyethylene block copolymer
PECEOL®	Glyceryl oleate (mono-, di- and triesters)
PLURONIC® F68	Polyoxypropylene/polyoxyethylene block copolymer
CAPROL® 10G40	Decaglycerol tetraoleate
MYVEROL® 18-99	Distilled monooleate from rapeseed oil
SPAN® 80	Sorbitan monooleate

Using the above procedures and excipients, Examples 1 to 27 were prepared to illustrate the binary compositions of the present invention. Example 28 was prepared as a comparative example of a formulation comprising a lipophilic solvent in the absence of a surfactant.

15

Example 1

<u>Component</u>	<u>%w/v</u>
Cyclosporin A	10
TWEEN® 80	25
MIGLYOL® 812	qs 100 ml

Example 2

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	20
Sesame oil	70

Example 3

5

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® RH40	5
CAPMUL® MCM	85

Example 4

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® RH40	15
CAPMUL® MCM	75

10 Example 5

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® RH40	10
CAPMUL® MCM	80

Example 6

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® RH40	25
CAPMUL® MCM	65

15

Example 7

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	40
MIGLYOL® 812	40
Hydrogenated Vegetable Oil	2
GELUCIRE® 33/01	8

Example 8

5

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	45
MIGLYOL® 812	45

Example 9

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	10
MAISINE®	80

10 Example 10

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	25
MAISINE®	65

Example 11

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	25
CAPMUL® GMO	65

15

Example 12

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
POLOXAMER® 237	5
CAPMUL® MCM	85

Example 13

5

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	5
PECEOL®	85

Example 14

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	10
PECEOL®	80

10 Example 15

<u>Component</u>	<u>%w/v</u>
Cyclosporin A	10
CREMOPHOR® EL	30
CAPMUL® MCM	15
MIGLYOL® 812	qs 100 ml

Example 16

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	15
PECEOL®	75

15

Example 17

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR <sup>®</sup> EL	25
PECEOL <sup>®</sup>	65

Example 18

5

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR <sup>®</sup> RH40	45
CAPMUL <sup>®</sup> MCM	45

Example 19

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
PLURONIC <sup>®</sup> F68	10
CAPMUL <sup>®</sup> GMO	80

10 Example 20

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
PLURONIC <sup>®</sup> F68	5
CREMOPHOR <sup>®</sup> EL	10
CAPMUL <sup>®</sup> GMO	75

Example 21

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR <sup>®</sup> EL	40
Propylene glycol laurate	50

15

Example 22

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	30
MYVEROL® 18-99	60

Example 23

5

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	20
MYVEROL® 18-99	30
Propylene glycol laurate	40

Example 24

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	30
Propylene glycol laurate	60

10 Example 25

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	5
SPAN® 80	15
MYVEROL® 18-99	70

Example 26

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	35
Oleic acid	15
MYVEROL® 18-99	40

Example 27

5

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CREMOPHOR® EL	30
CAPROL® 10G4O	30
MYVEROL® 18-99	30

Example 28

<u>Component</u>	<u>%w/w</u>
Cyclosporin A	10
CAPMUL® MCM	90

10 The oral bioavailability of the compositions of the present invention was evaluated in fasted beagle dogs as follows:

The compositions of Examples 1 to 19 and control samples consisting of the commercial cyclosporine products SANDIMMUNE® SEC (soft elastic capsule) and OPTORAL® SEC were filled into hard and soft gelatin capsules in quantities which, when  
 15 delivered to the subjects, delivered 50 mg/kg of cyclosporine to each dog. Blood concentration data was normalized to a 5 mg/kg dose in each dog. The soft elastic capsules were heat-sealed and all capsules were inspected to confirm the absence of leakage.

Six dogs were fasted and then at time t=0 were given one of the encapsulated compositions. Blood samples were taken at 15, 30, 60 and 90 minutes and at 2, 4, 6, 9, 12,  
 20 15 and 24 hours after dosing and analyzed for the blood concentration of cyclosporine. From this data the maximum blood serum concentration ( $C_{max}$ ), time from dosing until maximum blood serum concentration ( $T_{max}$ ) and total presence (area under curve, or AUC) as well as the respective standard deviations were computed and are shown below in Table 2:

Table 2  
Blood Concentrations of Cyclosporine  
After 5 mg/kg Oral Dosing of Dogs

<u>Example Number</u>	<u>C<sub>max</sub> (ng/ml)</u>	<u>T<sub>max</sub> (hours)</u>	<u>AUC (ng·hour/ml)</u>
1	629.8 ± 205.9	1.3 ± 0.4	3548.8 ± 1152.1
2	814.6 ± 156.5	1.3 ± 0.5	5519.2 ± 1181.6
3	472.7 ± 246.8	1.3 ± 0.4	2781.6 ± 1292.6
4	857.9 ± 357.7	1.3 ± 0.5	4879.3 ± 2274.0
5	866.3 ± 316.4	1.4 ± 0.4	4672.1 ± 1847.8
6	852.4 ± 454.2	1.8 ± 1.2	4664.8 ± 1555.9
7	1001.1 ± 264.2	1.7 ± 0.3	5974.7 ± 1729.3
8	1208.2 ± 335.3	1.4 ± 0.4	6495.6 ± 1452.0
9	1139.2 ± 400.1	1.1 ± 0.2	6824.5 ± 3392.2
10	945.1 ± 122.9	1.3 ± 0.3	5113.2 ± 1340.6
11	1132.0 ± 126.5	1.2 ± 0.3	6151.5 ± 1828.5
12	412.4 ± 183.9	2.4 ± 1.3	3233.2 ± 1690.6
13	733.2 ± 159.0	1.5 ± 0.5	4117.7 ± 1300.6
14	680.7 ± 110.9	1.2 ± 0.3	3731.4 ± 751.3
15	634.3 ± 453.3	0.9 ± 0.2	3369.8 ± 2682.3
16	971.7 ± 383.1	1.5 ± 0.5	5000.3 ± 1368.9
17	1078.2 ± 409.6	1.2 ± 0.3	5724.6 ± 1389.5
18	872.2 ± 226.8	1.5 ± 0.5	5551.6 ± 2243.9
19	819.3 ± 345.9	--	4718.3 ± 1850.5
20	798.4 ± 177.8	--	4627.7 ± 1028.1
21	993.7 ± 250.6	--	6055.2 ± 1159.2
22	973.0 ± 238.0	--	5539.7 ± 2569.7
23	946.9 ± 69.4	--	5175.0 ± 936.6
24	1002.2 ± 181.5	--	5580.9 ± 2165.2
25	663.2 ± 108.0	--	4557.4 ± 640.0
26	962.0 ± 149.3	--	5821.3 ± 397.9
27	871.2 ± 275.4	--	6730.5 ± 2708.6
28	448.8 ± 199.2	1.5 ± 0.3	2547.2 ± 1027.8



For SANDIMMUNE<sup>®</sup> SEC the  $C_{\max}$  was  $947.9 \pm 295.1$  ng/ml and the AUC was  $4837.7 \pm 1215.1$  ng·hour/ml. For OPTORAL<sup>®</sup> SEC the  $C_{\max}$  was  $1196.6 \pm 348.3$  ng/ml and the AUC was  $6049.1 \pm 971.1$  ng·hour/ml.

5

The foregoing detailed description and examples are merely illustrative and are not to be construed as limitations upon the scope of the invention, which is defined solely by the appended claims and their equivalents. It is expected that various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and may be made without departing from the spirit and scope of the invention.

10

What is claimed is:

1. A binary pharmaceutical composition comprising:
  - (a) a cyclosporine;
  - (b) a lipophilic phase; and
  - (c) a surfactant.
2. A binary composition according to Claim 1 wherein the cyclosporine comprises cyclosporin A.
3. A binary composition according to Claim 1 wherein (b) comprises a lipophilic component selected from the group consisting of a propylene glycol mono- and/or di-caprylate/caprate; a propylene glycol mono- and/or dilaurate; vegetable oil; corn oil; sesame oil; safflower oil; peanut oil; olive oil; cottonseed oil; glyceryl monostearate; glyceryl caprylate/caprate; glyceryl mono-, di- and/or trioleate; caprylic/capric triglyceride; a fractionated coconut oil; and mixtures thereof.
4. A binary composition according to Claim 1 wherein (b) comprises a fatty acid triglyceride.
5. A binary composition according to Claim 1 wherein (b) is caprylic/capric triglyceride.
6. A binary composition according to Claim 1 wherein (b) comprises glyceryl mono- or dicaprylate/caprate; glyceryl oleate; propylene glycol laurate; or a mixture thereof.
7. A binary composition according to Claim 1 wherein (c) comprises a nonionic surfactant.
8. A binary composition according to Claim 1 wherein (c) comprises a polyoxyethylene derivative of a natural or hydrogenated vegetable oil; a polyoxyethylene-sorbitan-fatty acid ester; a polyoxyethylene fatty acid ester; a saturated polyglycol glyceride; a sorbitan fatty acid ester; or a mixture thereof.
9. A binary composition according to Claim 1 wherein (c) comprises a polyoxyethylene glycolated natural or hydrogenated vegetable oil.

10. A binary composition according to Claim 1 comprising:
  - (a) between 0.03% and 25% by weight cyclosporine;
  - (b) between 10% and 90% by weight lipophilic phase; and
  - (c) between 5% and 90% by weight surfactant.
11. A binary composition according to Claim 1 comprising:
  - (a) between 5% and 15% by weight cyclosporine;
  - (b) between 20% and 85% by weight lipophilic phase; and
  - (c) between 10% and 60% by weight surfactant.
12. A binary composition according to Claim 1 comprising:
  - (a) 10% by weight cyclosporine;
  - (b) between 40% and 60% by weight lipophilic phase; and
  - (c) between 30% and 50% by weight surfactant.
13. A binary pharmaceutical composition comprising:
  - (a) cyclosporin A;
  - (b) propylene glycol laurate; and
  - (c) polyoxyl 35 castor oil.
16. A binary composition according to Claim 13 wherein (a), (b) and (c) are present in a ratio of approximately 10:50:40 by weight.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/04899

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/107 A61K9/48 A61K38/13

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 228 198 A (SANDOZ LTD) 22 August 1990 see page 29 - page 30; examples 1,2	1-12, 16
X	EP 0 760 237 A (CIPLA LIMITED) 5 March 1997 see page 2, line 47 - line 57 see page 4, line 23 - page 5, line 42	1-4, 7-12, 16
X	WO 96 33697 A (YISSUM RES DEV CO ; BENITA SIMON (IL); KLEINSTERN JACKIE (IL); GERS) 31 October 1996 see page 19; table VIII see page 9, line 6 - line 29	1, 2, 7, 8, 10, 11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### Special categories of cited documents

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "8" document member of the same patent family

Date of the actual completion of the international search

20 August 1998

Date of mailing of the international search report

26/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/US 98/04899

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2228198 A	22-08-1990	BE 1005236 A	08-06-1993
		CH 680650 A	15-10-1992
		CY 1886 A	05-04-1996
		DE 4005190 A	23-08-1990
		FR 2643262 A	24-08-1990
		HK 149595 A	29-09-1995
		IT 1240765 B	17-12-1993
		JP 1888154 C	07-12-1994
		JP 2255623 A	16-10-1990
		JP 6011703 B	16-02-1994
		US 5639724 A	17-06-1997
		US 5759997 A	02-06-1998
		US 5652212 A	29-07-1997
EP 0760237 A	05-03-1997	AU 6216296 A	06-03-1997
WO 9633697 A	31-10-1996	AU 692255 B	04-06-1998
		AU 2449195 A	18-11-1996

Form PCT/ISA/210 (patent family annex) (July 1992)

